Recruitment of PVT1 Enhances YTHDC1-Mediated m6A Modification of IL-33 in Hyperoxia-Induced Lung Injury During Bronchopulmonary Dysplasia

Tianping Bao, Xiangye Liu, Jian Hu, Mengmeng Ma, J. Li, Linxia Cao, Bingrui Yu, Huaiping Cheng, Sai Zhao, Zhaofang TianInflammation 2023 · DOI · OpenAlex

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease specifically affecting preterm infants, often exacerbated by hyperoxia-induced lung injury. This study investigates the role of the PVT1/IL-33 axis in BPD pathogenesis. Using mouse and human lung alveolar epithelial cell models, researchers identified that the long non-coding RNA (lncRNA) PVT1 recruits the m6A reader protein YTHDC1 to stabilize IL-33 mRNA through N6-methyladenosine (m6A) modification. Silencing PVT1 was found to suppress apoptosis and improve lung function, suggesting that the PVT1/IL-33 axis is a potential therapeutic target for hyperoxia-induced lung injury in BPD.

Introduction

Bronchopulmonary dysplasia (BPD) remains a significant challenge in neonatal intensive care. While life-saving, oxygen therapy can lead to hyperoxia-induced lung injury, characterized by the apoptosis of lung alveolar epithelial cells and impaired lung development. Recent advances in epitranscriptomics have highlighted the role of RNA modifications, particularly m6A methylation, in regulating gene expression and disease progression. This study explores how the lncRNA PVT1 and the cytokine IL-33 are regulated by m6A modifications in the context of BPD.

Epitranscriptomic Profiling in BPD

To understand the molecular landscape of hyperoxia-induced injury, researchers performed an epitranscriptomic microarray analysis comparing normal mice lungs with those stimulated by hyperoxia. The analysis revealed a significant shift in the RNA methylation landscape, with 817 upregulated and 626 downregulated mRNAs. Notably, both IL-33 and PVT1 exhibited significantly increased m6A RNA methylation levels and elevated expression in the hyperoxia-stimulated group.

mRNA expression levels of IL-33 are significantly elevated in the BPD mouse model compared to controls.

The PVT1/YTHDC1/IL-33 Axis

The study identified a specific signaling mechanism where PVT1 acts as a molecular scaffold. PVT1 recruits the m6A reader protein YTHDC1 to the IL-33 mRNA. This recruitment facilitates the m6A modification of IL-33, which enhances its stability and leads to higher protein expression. Elevated IL-33 levels, in turn, promote apoptosis in alveolar epithelial cells.

The percentage of m6A methylation on IL-33 mRNA is increased in the BPD group, supporting the role of epitranscriptomic regulation.

Experimental Results and Therapeutic Potential

In vitro experiments using MLE12 (mouse) and A549 (human) lung epithelial cells confirmed that hyperoxia triggers a substantial increase in PVT1 and IL-33 expression. Silencing PVT1 using shRNA significantly reduced apoptosis rates and shifted the balance of apoptotic markers, decreasing Bax and increasing Bcl-2 levels.

In vivo, silencing PVT1 in a BPD mouse model led to measurable improvements in lung architecture. Parameters such as radial alveolar count increased, indicating a rescue of lung development from hyperoxic damage. RNA-binding protein immunoprecipitation (RIP) assays further confirmed that silencing PVT1 reduced the binding of YTHDC1 to IL-33 by over 50%, validating the proposed mechanism.

Conclusion

The findings demonstrate that the PVT1/YTHDC1/IL-33 axis plays a critical role in hyperoxia-induced lung injury. By recruiting YTHDC1 to mediate the m6A modification and stabilization of IL-33, PVT1 exacerbates alveolar cell apoptosis. Targeting this axis, particularly through the silencing of PVT1, offers a promising therapeutic strategy to alleviate the severity of BPD in preterm infants. Future research may further elucidate the upstream "writers" of these m6A marks and explore the clinical feasibility of targeted lncRNA therapies.

Summary updated

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that specifically affects preterm infants. Oxygen therapy administered to treat BPD can lead to hyperoxia-induced lung injury, characterized by apoptosis of lung alveolar epithelial cells. Our epitranscriptomic microarray analysis of normal mice lungs and hyperoxia-stimulated mice lungs revealed elevated RNA expression levels of IL-33, as well as increased m6A RNA methylation levels of IL-33 and PVT1 in the hyperoxia-stimulated lungs. This study aimed to investigate the role of the PVT1/IL-33 axis in BPD. A mouse model of BPD was established through hyperoxia induction, and lung histological changes were assessed by hematoxylin-eosin staining. Parameters such as radial alveolar count and mean chord length were measured to assess lung function. Mouse and human lung alveolar epithelial cells (MLE12 and A549, respectively) were stimulated with hyperoxia to create an in vitro BPD model. Cell apoptosis was detected using Western blotting and flow cytometry analysis. Our results demonstrated that silencing PVT1 suppressed apoptosis in MLE12 and A549 cells and improved lung function in hyperoxia-stimulated lungs. Additionally, IL-33 reversed the effects of PVT1 both in vivo and in vitro. Through online bioinformatics analysis and RNA-binding protein immunoprecipitation assays, YTHDC1 was identified as a RNA-binding protein (RBP) for both PVT1 and IL-33. We found that PVT1 positively regulated IL-33 expression by recruiting YTHDC1 to mediate m6A modification of IL-33. In conclusion, silencing PVT1 demonstrated beneficial effects in alleviating BPD by facilitating YTHDC1-mediated m6A modification of IL-33. Inhibition of the PVT1/IL-33 axis to suppress apoptosis in lung alveolar epithelial cells may hold promise as a therapeutic approach for managing hyperoxia-induced lung injury in BPD.
BibTeX
@inproceedings{bao2023recruitment,
  author = {Tianping Bao and Xiangye Liu and Jian Hu and Mengmeng Ma and J. Li and Linxia Cao and Bingrui Yu and Huaiping Cheng and Sai Zhao and Zhaofang Tian},
  title = {{Recruitment of PVT1 Enhances YTHDC1-Mediated m6A Modification of IL-33 in Hyperoxia-Induced Lung Injury During Bronchopulmonary Dysplasia}},
  booktitle = {Inflammation},
  year = {2023},
  doi = {10.1007/s10753-023-01923-1},
}
Figure